Few relapses were reported among patients taking Abbott Laboratories (ABT:US)’ experimental hepatitis C treatment, according to a study.
The Abbott-funded research, dubbed Pilot, found that 10 of 11 patients who hadn’t received prior treatment were cured 24 weeks after the end of a 12-week treatment on the drugmaker’s hepatitis C drugs ABT-072 and ABT-450 with ribavirin, the Abbott Park, Illinois-based company said today in a statement.
After 36 weeks, another patient relapsed, while no more relapses were observed after 48 weeks, the company said.
To contact the reporter on this story: Makiko Kitamura in Barcelona, Spain, via email@example.com
To contact the editor responsible for this story: Phil Serafino at firstname.lastname@example.org